Your browser doesn't support javascript.
loading
Multifunctional Biomimetic Nanovaccines Based on Photothermal and Weak-Immunostimulatory Nanoparticulate Cores for the Immunotherapy of Solid Tumors.
Li, Jiachen; Huang, Di; Cheng, Ruoyu; Figueiredo, Patrícia; Fontana, Flavia; Correia, Alexandra; Wang, Shiqi; Liu, Zehua; Kemell, Marianna; Torrieri, Giulia; Mäkilä, Ermei M; Salonen, Jarno J; Hirvonen, Jouni; Gao, Yan; Li, Jialiang; Luo, Zhenyang; Santos, Hélder A; Xia, Bing.
Afiliação
  • Li J; College of Science, Nanjing Forestry University, Nanjing, 210037, China.
  • Huang D; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, FI-00014, Finland.
  • Cheng R; Department of Biomedical Engineering and W.J. Kolff Institute for Biomedical Engineering and Materials Science, University of Groningen/University Medical Center Groningen, Ant. Deusinglaan 1, Groningen, 9713 AV, The Netherlands.
  • Figueiredo P; College of Science, Nanjing Forestry University, Nanjing, 210037, China.
  • Fontana F; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, FI-00014, Finland.
  • Correia A; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, FI-00014, Finland.
  • Wang S; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, FI-00014, Finland.
  • Liu Z; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, FI-00014, Finland.
  • Kemell M; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, FI-00014, Finland.
  • Torrieri G; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, FI-00014, Finland.
  • Mäkilä EM; Department of Chemistry, University of Helsinki, Helsinki, FI-00014, Finland.
  • Salonen JJ; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, FI-00014, Finland.
  • Hirvonen J; Laboratory of Industrial Physics, Department of Physics and Astronomy, University of Turku, Turku, FI-20014, Finland.
  • Gao Y; Laboratory of Industrial Physics, Department of Physics and Astronomy, University of Turku, Turku, FI-20014, Finland.
  • Li J; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, University of Helsinki, Helsinki, FI-00014, Finland.
  • Luo Z; College of Science, Nanjing Forestry University, Nanjing, 210037, China.
  • Santos HA; College of Science, Nanjing Forestry University, Nanjing, 210037, China.
  • Xia B; College of Science, Nanjing Forestry University, Nanjing, 210037, China.
Adv Mater ; 34(9): e2108012, 2022 Mar.
Article em En | MEDLINE | ID: mdl-34877724
ABSTRACT
An alternative strategy of choosing photothermal and weak-immunostimulatory porous silicon@Au nanocomposites as particulate cores to prepare a biomimetic nanovaccine is reported to improve its biosafety and immunotherapeutic efficacy for solid tumors. A quantitative analysis method is used to calculate the loading amount of cancer cell membranes onto porous silicon@Au nanocomposites. Assisted with foreign-body responses, these exogenous nanoparticulate cores with weak immunostimulatory effect can still efficiently deliver cancer cell membranes into dendritic cells to activate them and the downstream antitumor immunity, resulting in no occurrence of solid tumors and the survival of all immunized mice during 55 day observation. In addition, this nanovaccine, as a photothermal therapeutic agent, synergized with additional immunotherapies can significantly inhibit the growth and metastasis of established solid tumors, via the initiation of the antitumor immune responses in the body and the reversion of their immunosuppressive microenvironments. Considering the versatile surface engineering of porous silicon nanoparticles, the strategy developed here is beneficial to construct multifunctional nanovaccines with better biosafety and more diagnosis or therapeutic modalities against the occurrence, recurrence, or metastasis of solid tumors in future clinical practice.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nanocompostos / Nanopartículas / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nanocompostos / Nanopartículas / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article